ClinicalTrials.gg
RecruitingNCT06001827SAVE-FistulaSUpdated Feb 17, 2026

SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study

An interventional study of SelfWrap Bioabsorbable Perivascular Wrap and Untreated AVF Control in Chronic Kidney Diseases, End Stage Renal Disease and Arteriovenous Fistula, sponsored by VenoStent. Recruiting at 28 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-17.

Primary conditionKidney Failure, ChronicRegistry: Renal Insufficiency, ChronicReclassifiedWhy we changed it
Registry
Renal Insufficiency, Chronic — the first condition term the registry derived for this study.
ClinicalTrials.gg
Kidney Failure, Chronic
Why
  1. The study's listed conditions name Kidney Failure, Chronic, a narrower term within Renal Insufficiency, Chronic.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by VenoStent · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 765 studies in Kidney Failure, Chronic with a site in United States — 65 open to participants now, 96 under way, 9 of them phase 3. Kidney Failure, Chronic · United States.

Planned enrollment
55th of 638
600 · median 48
Started
2024
with 23 others
No phase
287 of 765
28 open now
Primary completion
2027-06
later than 39 of 95 live
Registered
703rd of 765
by date

Among the 765 studies in Kidney Failure, Chronic with a site in United States, this one is the 55th largest by planned enrollment of the 638 interventional ones that give a count, is one of 24 that started in 2024, is one of 287 with no phase, reaches primary completion later than 39 of the 95 other live ones, and was the 703rd registered.

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

65 of the 765 studies in Kidney Failure, Chronic with a site in United States are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 765 studies in Kidney Failure, Chronic with a site in United States, or all of them as a file.
02

Study summary

This is a prospective, randomized, multi-center clinical trial for chronic kidney disease (CKD) patients referred for creation of a new arteriovenous fistula (AVF) in order to assess the safety and effectiveness of SelfWrap, a bioabsorbable perivascular wrap.

Read the detailed description

This is a multi-center, prospective, randomized, double-arm, single-blind, evaluator-blinded clinical trial for CKD patients referred for creation of a new arteriovenous fistula (AVF). This study will involve approximately 600 participants from up to 30 investigational sites, randomized 1:1 to treatment with the SelfWrap or the untreated AVF control (i.e. standard of care, SOC). Participants will be followed for a duration of 36 months.

03

Conditions studied

  • Chronic Kidney Diseases
  • End Stage Renal Disease
  • Arteriovenous Fistula
  • Hemodialysis Access Failure
  • ESRD
  • Vascular Access Complication
  • Renal Failure
  • Catheter Complications
  • Catheter Dysfunction
  • Renal Insufficiency

Keywords

  • Vascular Surgery
  • Vascular Access
  • Nephrology
  • Bioabsorbable
  • Perivascular Wrap
  • External Support
  • Hemodialysis
  • Dialysis
  • Chronic Kidney Disease
  • End Stage Renal Disease
  • Arteriovenous Fistula
  • AVF
04

In context

Kidney Failure, Chronic Reclassified

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

This study's planned enrollment of 600 is above the median of 57 across 1,573 interventional studies indexed under Kidney Failure, Chronic.

Browse Kidney Failure, Chronic studies →

Lead sponsor

VenoStent is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Compared within Kidney Failure, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Renal Insufficiency, Chronic. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age of at least 18 years
  • Referred for creation of a new AVF
  • Willing and able to comply with study requirements, communicate with the study team, and attend follow up visits over a period of 36 months

Exclusion criteria

Exclusion Criteria:

  • Planned index procedure to revise or repair an existing fistula
  • Target artery inner diameter \< 2.0 mm, as measured by ultrasound while the target arm is under tourniquet pressure and anesthesia
  • Target vein inner diameter \< 2.0 mm, as measured by ultrasound while the target arm is under tourniquet pressure and anesthesia
  • Significant (at least 50%) stenosis at the target vein on the side of surgery (between the planned anastomosis site and the axillary vein), as diagnosed by preoperative ultrasound
  • Known central venous stenosis of at least 50% on the side of surgery
  • Presence of a stent or a stent graft within the access circuit
  • Known or suspected coagulation disorder that, in the opinion of the Investigator, puts too much risk on the patient for AVF creation
  • Known or suspected active infection at the time of surgery
  • Congestive heart failure class 4
  • Prior steal on the side of surgery;
  • Enrolled in another drug, device, or biological study, or was previously enrolled in this study
  • less than 12 months
  • Expected to undergo kidney transplant surgery within 6 months of enrollment
  • Expected to undergo home hemodialysis
  • Females of (premenopausal and not surgically sterile) without documented current negative pregnancy test at screening
  • Presence of a comorbid condition that, in the opinion of the Investigator, may significantly confound the collection of safety and efficacy data in this study
  • Unwillingness or inability to give consent and/or comply with the study follow up schedule
  • Any health condition, which in the opinion of the Investigator, would interfere with the safety of the participant or the participant's ability to comply with the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    Treatment Arm

    Treated with SelfWrap Bioabsorbable Perivascular Wrap during AVF creation surgery

    Device: SelfWrap Bioabsorbable Perivascular Wrap

  • Sham comparator
    Control Arm

    AVF creation surgery without any intervention (untreated AVF control, or standard of care)

    Procedure: Untreated AVF Control

Interventions

  • DeviceSelfWrap Bioabsorbable Perivascular Wrap

    SelfWrap is applied during arteriovenous fistula (AVF) creation surgery. It provides mechanical support to improve maturation and patency of AVFs.

    Also known as: SelfWrap

  • ProcedureUntreated AVF Control

    AVF creation surgery without any intervention

    Also known as: Standard of Care

07

What researchers measure

Primary outcomes

  1. Unassisted Maturation by 180 days

    A participant who is either 1) on hemodialysis on or before day 150 and the AVF has been cannulated with two needles for at least 75% of dialysis sessions within any 4 consecutive week period to achieve the prescribed dialysis by the 180 day follow up, and did not require any facilitative endovascular or surgical intervention to achieve this, or 2) is not on hemodialysis on or before day 150, but ultrasound measurements by the 180 day follow up indicate a proximal arterial flow rate of at least 500 mL/min and a vein inner diameter of at least 5.0 mm at 5 - 8 cm from the anastomosis, and did not require any facilitative endovascular or surgical intervention through the 180 day follow up.

    Time frame: Assessed at up to 6 months

  2. Freedom from access-related adverse events through 30 days

    Freedom from access-related adverse events through 30 days

    Time frame: Assessed through 30 days

08

Study locations

28 of 28 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Jun 2027, 41 months after the start.

Of 78 industry-sponsored interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 40. This study's planned 41 months is above that.

Counting every sponsor, half of 427 studies reached it within 22 months; a quarter within 8 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2023
First posted
Aug 21, 2023
StartActual
Jan 3, 2024
Primary completionEst.
Jun 2027
CompletionEst.
Dec 2029
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06001827
Lead sponsor
VenoStent
Responsible party
Sponsor
First posted
Aug 21, 2023
Start date
Jan 3, 2024
Primary completion
Jun 2027 (estimated)
Completion
Dec 2029 (estimated)
Last update
Feb 17, 2026

Study contacts

Mark Barakat, MD
Contact
mark.barakat@venostent.com
(832) 429-5362
Timothy Boire, PhD
study director · VenoStent, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion